BLO Cannabix Technologies Inc

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market

VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into its first sale agreement for its BreathLogix unmanned alcohol screening technology. The Company will be delivering its BreathLogix technology to a European maritime shipping company that is seeking to increase operational safety amongst its crew members with pre-access breath alcohol testing. The system will be integrated with the cloud-based “BreathLogix Connect” platform, powered by Amazon Web Services, enabling real-time alerts, centralized data management, and seamless reporting. Additionally, the device will integrate facial recognition technology for rapid and secure crew member identification. The BreathLogix alcohol testing solution is targeted to various industries including mining, oil and gas, industrial, trucking, warehousing and maritime vessels to enhance operational safety.

Figure 1. BreathLogix Alcohol device available with contactless and straw modes for rapid workplace pre-access alcohol screening

This announcement comes on the heels of the Company completing its first commercial production run commenced this summer. Earlier this year, the Company’s BreathLogix “Workplace Series” device was approved by National Highway Traffic Safety Association (NHTSA) to be added to the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screen devices.

BreathLogix unmanned alcohol screening devices rapidly check for breath alcohol and simultaneously takes a photo of the user to help confirm and record identity (Figure 1 and 2). The device delivers precise Blood Alcohol Content (BAC or BrAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘BreathLogix Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.   

Figure 2. BreathLogix Alcohol Screening Devices by Cannabix Technologies Inc.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO

Cannabix Technologies Inc.

For further information, contact the Company at

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements



This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies; positive developments with contract manufacturers; the completion of pre-validation or validation testing; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors and or contract manufacturers; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos accompanying this announcement are available at



EN
30/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cannabix Technologies Inc

 PRESS RELEASE

Cannabix Technologies announces Non-Brokered LIFE Private Placement

Cannabix Technologies announces Non-Brokered LIFE Private Placement NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) announces a non-brokered private placement for a minimum of 2,127,659 units (the "Units") of the Company at a price of C$0.47 per Unit for aggregate gross proceeds to the Company of $1,000,000 and up to a maximum of 4,255,319 Units for aggregate gross proceeds of $2,000,000 (the "Offering"). The O...

 PRESS RELEASE

Cannabix Technologies Granted Patent from USPTO for Contactless Breath...

Cannabix Technologies Granted Patent from USPTO for Contactless Breath Analysis VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to report that the United States Patent and Trademark Office (USPTO) has granted patent No. 18/1729,658 entitled, “Contact-Free Breath Analysis Device and Method” to the Company. This patent is centered on innovations made by Cannabix and its dual mode contactless (and traditional mouthpiece) breath capture and analysis technology used...

 PRESS RELEASE

Cannabix Technologies announces Stock Option Grant

Cannabix Technologies announces Stock Option Grant VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it has granted 2,500,000 incentive stock options (“the Options”) to certain directors and consultants of the Company, exercisable at $0.55. 700,000 of the Options will expire in five years from the date of grant, 800,000 will expire in two years (subject to vesting provisions) from the date of grant and 1,000,000 will expire after 1 year from the date of grant. The Opti...

 PRESS RELEASE

Cannabix Technologies Delivers BreathLogix Alcohol Screening Device to...

Cannabix Technologies Delivers BreathLogix Alcohol Screening Device to Oilfield Transportation Services Company VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report the delivery of its BreathLogix technology to an oil and gas transportation services company located in northern Alberta, Canada. The BreathLogix system is designed for rapid, unmanned testing and is tailored for industries where safety is critical...

 PRESS RELEASE

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Scre...

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into its first sale agreement for its BreathLogix unmanned alcohol screening technology. The Company will be delivering its BreathLogix technology to a European maritime shipping company that is seeking to increase operational safety amo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch